The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients
American Journal of Nephrology · 2024
DOI: 10.1159/000538231 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Yu-Lien Tsai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, En Chu Kong Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Kidney Transplantation, Virus Activation, Hepatitis B Surface Antigens, Graft Survival. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Introduction
Hepatitis B virus (HBV) infection is prevalent in Asia including Taiwan. We retrospectively evaluated the risk of HBV reactivation and clinical outcomes in HBV+ and HBV– kidney transplant recipients.
Methods
Patients who underwent kidney transplantation between January 2004 and December 2021 were reviewed. The outcomes of interest included risks of HBV reactivation and patient/graft survival.
Results
We identified 337 patients (47.5 ± 12 years) in our final cohort. Fifty-two (15.4%) had hepatitis B surface antigen (HBsAg) positive at the time of transplantation. Seventeen developed viral reactivations, with 41.2% of them accompanied by active hepatitis. The graft survival, acute rejection rate, and cancer development after kidney transplantation did not differ in terms of HBsAg status. The Cox multivariate analysis indicated the HBV reactivation risk was increased by a lack of pretransplant anti-HBV medication (hazard ratio [HR], 5.95; 95% confidence interval [CI], 1.31–27.02; p = 0.021) or an absence of lifelong antiviral therapy (HR: 3.14; 95% CI: 1.01–9.74; p = 0.047).
Conclusion
Individuals, independent of HBsAg status, had similar prognosis in terms of patient and graft survival, acute rejection rate, and cancer development. The absence of either pretransplant anti-HBV medication or lifelong antiviral therapy was significantly associated with an increased risk of HBV reactivation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, En Chu Kong Hospital, New Taipei City, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- School of Medicine, College of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
- Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Trauma, Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
Zitieren
APA
Tsai, Y. L., Chung, M. H., Lin, N. C., Chen, C. Y., Lin, Y. P., Tsai, M. T., Tsai, H. L., Chen, Y. A., Ou, S. M., Chu, C. J., Wu, T. H., & Tsai, C. Y. (2024). The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. American Journal of Nephrology. https://doi.org/10.1159/000538231
Vancouver
Tsai YL, Chung MH, Lin NC, Chen CY, Lin YP, Tsai MT, et al. The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. American Journal of Nephrology. 2024. doi:10.1159/000538231
BibTeX
@article{Tsai2024,
author = {Tsai, Yu-Lien and Chung, Meng-Hsuan and Lin, Niang-Cheng and Chen, Cheng-Yen and Lin, Yao-Ping and Tsai, Ming-Tsun and Tsai, Hsin-Lin and Chen, Yee-An and Ou, Shuo-Ming and Chu, Chi-Jen and Wu, Tsai-Hung and Tsai, Chang-Youh},
title = {The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients},
journal = {American Journal of Nephrology},
year = {2024},
doi = {10.1159/000538231}
}
EUVIMED